ArticleJournal of cancer survivorship : research and practice2025
Prevalence and determinants of cigarette-cannabis co-use among US cancer survivors.
Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe estimated the prevalence of cigarette-cannabis co-use and investigated the individual-level factors associated with cigarette-cannabis co-use among adult (aged ≥ 18) cancer survivors.
methodsWe used population-based data from the 2022 Behavioral Risk Factor Surveillance System. The sample included 9,323 (weighted 2,711,650) adult cancer survivors residing in 16 US states and two US territories. The outcome was cigarette-cannabis co-use, examined using multinomial multivariable logistic regression models.
resultsOverall, 81.83% self-reported as white, 58.97% women, and 57.69% aged ≥ 65. About 12.00% reported current cigarette use, 10.36% past 30-day cannabis use, and 3.28% cigarette-cannabis co-use. The odds of cigarette-cannabis co-use were greater for younger survivors (18-49 years), those with high school or less education, not in the workforce, and divorced, separated, widowed, or never married individuals. Further, survivors with ≥ 3 comorbidities (vs. no-comorbidity), ≥ 14 days of poor mental health days (vs. none), and ≥ 14 days of poor physical health (vs. none) in the past month also had increased odds of cigarette-cannabis co-use.
conclusionsThe study findings suggest that certain subgroups of cancer survivors are more likely to engage in cigarette-cannabis co-use, and these patterns are associated with individual-level factors. IMPLICATIONS FOR CANCER SURVIVORS: New strategies and tailored interventions targeting cigarette-cannabis co-use among cancer survivors are critically needed to improve the overall well-being of cancer survivors. Future research should explore additional factors to fully understand cigarette-cannabis co-use in cancer survivors.
Indexed as
Identifiers
40156654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.